µ¼Ó²¡Àí»úÖÆ¡¢ÐÂÒ©Ñз¢¡¢ÕïÁÆÖÎÀíÈ«·½Î»ÁýÕÖ£¬Ò»ÆðÀ´¿´°¢¶û´Äº£Ä¬²¡ÁìÓò×îнøÕ¹£¡

 

2023Äê11ÔÂ18ÈÕ£¬ÓÉÖйúÄÔ½¡¿µÐж¯×¨¼ÒίԱ»áÖ¸µ¼£¬¾«×¼Ò½Ñ§Ñо¿Ó빤ҵÉú³¤ÁªÃ˼°ÉϺ£Ò½Ñ§Á¢ÒìÉú³¤»ù½ð»áÖ÷°ì¡¢ng28ÄϹ¬´óÁ¦Ö§³ÖµÄ2023Äê°¢¶û´Äº£Ä¬²¡á¯ÁëÂÛ̳ÓÚ±±¾©Ê¢´óÕÙ¿ª£¬º£ÄÚÍâ¶àλÈÏÖªÕÏ°­ÁìÓòµÄר¼ÒѧÕßÆë¾ÛÒ»ÌÃ£¬Î§ÈÆÄÔ½¡¿µ¡¢°¢¶û´Äº£Ä¬²
¡£¨AD£©²¡Àí»úÖƼ°ÉúÎï±ê¼ÇÎï¡¢¼²²¡ÐÞÊÎÖÎÁÆ£¨DMT£©Ò©Îï×îÐÂÑо¿Êý¾Ý¡¢»¼ÕßÖÎÀíµÈÈȵ㻰ÌâÕ¹¿ªÁËÉîÈë̽ÌÖ£¬¿ªÆôADÁìÓò¿çʱ´úÉú³¤µÄл¨Ñù
¡£

ÔÚ¿ª³¡Ö´ǻ·½Ú£¬´ó»áÖ÷ϯÉϺ£Ò½Ñ§Á¢ÒìÉú³¤»ù½ð»áÖ´ÐÐÀíʳ¤Íõ²¨Å®Ê¿¡¢Ê׶¼Ò½¿Æ´óѧÐûÎäÒ½Ôº¼Ö½¨Æ½½ÌÊÚ¡¢¸£½¨Ò½¿Æ´óѧÁ¥ÊôЭºÍÒ½Ôº³ÂÏþ´º½ÌÊÚÖ¿ª³¡´Ç£¬¾ùÌåÏÖÄ¿½ñADÁìÓòÒÑÓ­À´ÁËÀúÊ·ÐԵı¼ÌÚÓëÍ»ÆÆ
¡£

ͼ ÉϺ£Ò½Ñ§Á¢ÒìÉú³¤»ù½ð»áÖ´ÐÐÀíʳ¤Íõ²¨Å®Ê¿

ͼ Ê׶¼Ò½¿Æ´óѧÐûÎäÒ½Ôº¼Ö½¨Æ½½ÌÊÚ

ͼ ¸£½¨Ò½¿Æ´óѧÁ¥ÊôЭºÍÒ½Ôº³ÂÏþ´º½ÌÊÚ

 

¼¯»áÒÁʼ£¬Ê׶¼Ò½¿Æ´óѧÁ¥Êô±±¾©Ìì̳ҽԺÍõÓµ¾ü½ÌÊÚÊ×ÏÈΪÎÒÃǽéÉÜÁËÄÔ½¡¿µÖÎÀíÖÐÐĵĿ´·¨¡¢ÏÖ×´ÓëÕ¹Íû
¡£ÄÔ½¡¿µÊÇʵÏÖ¿ÉÁ¬ÐøÉú³¤Ä¿±êµÄ½¹µã£¬²¢Ã÷È·Ìá³öÁËÄÔ½¡¿µ½ç˵µÄËÄÏîÄÚÈÝ£¬¼´ÄԽṹÕý³£¡¢ÄÔ¹¦Ð§Õý³£¡¢Éç»áÊÊÓ¦Á¼ºÃ¡¢ÎÞÉñ¾­¾«Éñ¼²²¡£¬²¢Ö¸³öÄÔ½¡¿µÖÎÀíÖÐÐÄÓ¦ÒÔÕâËĸöά¶ÈΪ½¹µãÃ÷È·Ö°Äܶ¨Î»£¬ÒÔ¸üºÃµØÍƶ¯ÎÒ¹úÄÔ½¡¿µÉú³¤
¡£

ͼ ÍõÓµ¾ü½ÌÊÚ

 

Í»ÆƱÚÀÝ¡¢¿ªÆôδÀ´£¬ADÕïÁÆ¿ªÆôÐÂƪÕÂ

Ëæ×ÅADÖ²¡»úÖƵÄÃ÷ÎúÓëDMTÒ©ÎïµÄÉú³¤£¬½üÄêÀ´ADÉúÎï±ê¼ÇÎïµÄÑо¿Èç»ðÈçݱ
¡£ÖÐÄÏ´óѧÏæÑÅÒ½ÔºÉòè´½ÌÊÚ·ÖÏíÁËADÉúÎï±ê¼ÇÎïµÄ×îÐÂÑо¿½øÕ¹
¡£ÔÚ½ñÄêµÄ°¢¶û´Äº£Ä¬²¡Ð­»á¹ú¼Ê¼¯»á£¨AAIC£©´ó»áÉÏÐû²¼ÁËAD×îÐÂÕï¶Ï±ê×¼£¬½¨Òéͨ¹ý½¹µãÉúÎï±ê¼ÇÎｫAD½øÐзÖÆÚ¼°Õï¶ÏAD£¬ÓÉ´ËÔÚADµÄÁÙ´²·ÖÆÚÖÐÔö¼ÓÁË0½×¶Î£¨stage 0£©£»±ðµÄ»¹½éÉÜÁ˶àÖÖѪҺÉúÎï±ê¼ÇÎïµÄÑо¿½øÕ¹¼°ÆäÔÚÕïÁÆÖеÄÓ¦ÓüÛÖµ£¬²¢¶ÔA¦ÂºÍTau-PETÔÚADÕï¶ÏÖеĺÏÀíÓ¦Óøø³öÖî¶à½¨Òé
¡£

ͼ Éòè´½ÌÊÚ

 

Ê׶¼Ò½¿Æ´óѧÐûÎäҽԺκ´ä°Ø½ÌÊÚ½â¶ÁÁË×îÐÂDMTÒ©ÎïÏà½ÏÓڹŰåÒ©ÎïµÄÐÂÄ¿±êºÍÐÂÒªÇó£¬ÈçÇå³ý²¡Àí²úÆ·ºÍÑÓ»º¼²²¡½ø³Ì£¬¶øÂØ¿¨Ä¹µÄÑо¿Êý¾Ý¶¼ºÜºÃµÄÖ§³ÖÁËDMTµÄÖÎÁÆ»ñÒæ
¡£ÂØ¿¨Ä¹¾ßÓÐÃ÷È·µÄÁÆЧºÍÁ¼ºÃµÄÄþ¾²ÐÔºÍÄÍÊÜÐÔ£¬´ú±í¿¹A¦Âµ¥¿¹Ò©ÎïÍ»ÆÆÖØΧ¡¢¿ªÆôDMTʱ´úµÄÐÂƪÕÂ
¡£

ͼ κ´ä°Ø½ÌÊÚ

κ´ä°Ø½ÌÊÚ½éÉܵÀ£¬ÂØ¿¨Ä¹Á¬ÐøÖÎÁƿɼõ»ºÈÏÖªºÍ¹¦Ð§µÄË¥Í˺͸üºÃά³Ö¹¦Ð§£¬ÕÕÁϵ£¸º¸üÉÙ£¬ÓÈÆäÔÚµÍTauˮƽÑÇ×飨¼´¸üÔçÆÚµÄAD»¼Õߣ©ÖпÉÑÓ»ºÁÙ´²³Õ´ôÆÀ·Ö×ܺÍÁ¿±í£¨CDR-SB£©Ë¥ÍË549%£¬ÌáʾԽÔçÖÎÁÆ£¬»¼Õß»ñÒæÔ½¶à
¡£²»µ«Èç´Ë£¬ÔçÆÚÆô¶¯ÂØ¿¨Ä¹ÖÎÁÆ£¬»¹¿ÉÈÃ76%µÄ¸üÔçÆÚAD»¼Õß»ñµÃÈÏÖªºÍ¹¦Ð§Î¬³Ö£¬60%»¼ÕßµÄÈÏÖªºÍ¹¦Ð§»ñµÃ¸ÄÉÆ^[2]
¡£

ͼ ÔçÆÚÆô¶¯ÂØ¿¨Ä¹ÖÎÁÆÈÏÖªºÍ¹¦Ð§Î¬³Ö¡¢¸ÄÉÆ

 

ÔÚADÕï¶Ï¼°ÖÎÁÆÁìÓò¶¼È¡µÃÍ»ÆÆÈ·µ±ÏÂ£¬ADÁÙ´²ÕïÁÆʵ¼ùÒ²ÌáÉÏÁËÒéÊÂÈÕ³Ì
¡£¸çÂ×±ÈÑÇ´óѧLawrence Honig½ÌÊÚΪÎÒÃǽøÐÐÁËÖ÷ÌâΪ¡°Healthcare System Readiness for New Treatments for Alzheimer Disease¡±µÄÊÚ¿Î£¬Lawrence½ÌÊÚÖ¸³ö£¬ADÔ´ÐÔMCl¼°Çá¶ÈADµÈÔçÆÚAD»¼Õß¡¢ÄÔ¼¹Òº»òPET£¨ÉõÖÁѪ½¬£©¼ì²é½á¹ûÈ·ÈÏÓеí·ÛÑùÂѰ׵Ļ¼ÕßÈËȺӦ¾¡Ôç½ÓÊÜDMTÖÎÁÆ
¡£

ͼ Lawrence Honig½ÌÊÚ

 

ÔÚÉÏÎ缯»áµÄ×îºó£¬½â·Å¾ü×ÜÒ½Ôº½âºã¸ï½ÌÊÚÖ÷³ÖÁËÌÖÂÛ»·½Ú£¬Õã½­´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½ÔºÂÞ±¾Ñà½ÌÊÚ¡¢ÇൺÊÐÊÐÁ¢Ò½ÔºÌ·À¼½ÌÊÚÓëLawrence Honig½ÌÊÚ¾ÍÄ¿½ñµÄDMTÒ©ÎïÊÇ·ñÄܹ»ÕæÕýΪAD»¼Õß´øÀ´»ñÒæ¡¢DMTÒ©ÎïÈçºÎ²Å»ªÔÚÁÙ´²Êµ¼ùÖз¢»Ó×î´ó¼ÛÖµÒÔ¼°ÄÔ½¡¿µÖÐÐĵĽ¨ÉèÕ¹¿ªÁ˾«²ÊÌÖÂÛ
¡£

ͼ ´ó¿§É³·¢Ðã

 

×·¸ùËÝÔ´£¬Ã÷È·²¡Àí»úÖÆ£¬Íƶ¯ADÕïÁÆÉú³¤

µ±ÌìÏÂÎ缯»á¿ªÊ¼Ê±£¬´ó»áÖ÷ϯ±±¾©´óѧµÚÁùÒ½ÔºÓÚÐÀ½ÌÊÚ¡¢É½¶«µÚÒ»Ò½¿Æ´óѧÁ¥ÊôÊ¡Á¢Ò½Ôº¶Åâù·å½ÌÊÚÖ´ǵÀ£¬ÄîÄî²»Íü£¬±ØÓлØÏì£¬¾­¹ý¶þÊ®¶àÄêÀ´µÄ²»Ð¸Å¬Á¦£¬ADÕïÁÆÁìÓòÖÕÓÚÏÆ¿ªÁËÈ«ÐÂƪÕÂ
¡£

ͼ ÓÚÐÀ½ÌÊÚ

 

ͼ ¶Åâù·å½ÌÊÚ

 

ÉϺ£½»Í¨´óѧÁ¥ÊôµÚÁùÈËÃñÒ½Ôº¹ùÆðºÆ½ÌÊÚ½éÉÜÁ˽üÆÚAD×îеIJ¡Àí»úÖÆ·¢Ã÷
¡£¶àÖÖADÖ²¡»úÀíµÄ¼Ù˵ÓÐÁËеÄÀ©³äºÍ·¢Ã÷£¬¼´A¦Â¹Ñ¾ÛÌå¿É×÷Ϊ¡°ÖÖ×Ó¡±¼ÓËÙA¦Â³Á»ý£¬Í¬Ê±¿ÉÓëTauÂÑ°×Эµ÷×÷ÓÃ^[4,5]
¡£ÂØ¿¨Ä¹Í¨¹ýÓÕµ¼Ð¡½ºÖÊϸ°ûÇå³ý×î¾ß¶¾ÐÔµÄA¦Â¹Ñ¾ÛÌåºÍÔ­ÏËά£¬²¢Ô¤·À°ß¿éÉú³É£¬Í¬Ê±¼õÉÙÏÂÓÎTau²¡Àí½øÕ¹£¬ÒÔ´ËÓÐЧÑÓ»ºAD½øÕ¹£¬ÑéÖ¤ÁËÒÔ¡°A¦Â¼¶ÁªÑ§Ëµ¡±ÎªÀíÂÛ»ù´¡µÄÖÎÁÆÕ½ÂÔ^[6,7]
¡£

ͼ ¹ùÆðºÆ½ÌÊÚ

 

ËÄ´¨´óѧ»ªÎ÷Ò½Ôº³ÂÇÛ½ÌÊÚÖ¸³ö£¬A¦ÂÔÚÌåÄÚÒÔ¶àÖÖÐÎʽ±£´æ£¬µ±A¦Â¾Û¼¯³Á»ý´óÓÚÇå³ýʱ»áÔì³É³Á»ý¹ýÔØ£¬´Ó¶øÓÕ·¢AD^[8]
¡£A¦ÂÒì³£¾Û¼¯ºÍÍ»´¥¹¦Ð§Ê§µ÷±¬·¢ÔÚTau²¡ÀíÁ÷´«¡¢´óÄԽṹ¸Ä±ä£¨Éñ¾­ÔªÉ¥Ê§£©¡¢·ºÆðÁÙ´²ÌåÏÖ»òÖ¢×´µÈ½×¶Î֮ǰ£¬Æä³Á»ýÓëADµÄ½øչΣº¦¾ßÓÐÏà¹ØÐÔ£¬Òò´ËA¦Â³ÉΪĿǰADÒ©ÎïÑз¢¹ÜÏßÖеÄÈȵã×÷ÓðÐλ^[9]
¡£

ͼ ³ÂÇÛ½ÌÊÚ

 

ÄÏ¿ª´óѧÁ¥ÊôÌì½òÊл·ºþÒ½Ôº¼ÍÓ½ÌÊÚÒÔ¡°AD£º´ÓÁÙ´²µ½²¡ÀíÕï¶Ï¡±·ÖÏíÁËÈçºÎ¾«×¼ÔçÆÚAD»¼Õß£¬²¡Àí½á¹ûÊÇÕï¶ÏADµÄ½ð±ê×¼£¬µ«ÈçºÎÒÔ¸üСµÄ´´ÉËʵÏÖAD»¼ÕßµÄÔçÆÚÕï¶Ï£¿ÔÚ±¾´Î±¨¸æÖÐ£¬¼ÍÓ½ÌÊÚÖ¸³öÁ˽ṹӰÏñѧ¡¢·Ö×ÓÓ°Ïñѧ¡¢ÑªÒº±ê¼ÇÎïÔÚADÕï¶ÏÖеIJî±ð×÷ÓÃ
¡£

ͼ ¼ÍÓ½ÌÊÚ

 

½ÓÏÂÀ´½â·Å¾ü×ÜÒ½Ôº¼Ö½¨¾ü½ÌÊÚÏêϸÂÛÊöÁË¡°A¦Â·Ö×ÓÓ°Ïñ¼¼Êõ¡±ÔÚÖйúµÄÓ¦ÓÃÏÖ×´£¬Ìá³öA¦Â-PETÓ°ÏñѧÊÊÓÃÓÚÁ¬Ðø»ò½øÕ¹ÐԵIJ»¿É½âÊ͵ÄMCI»¼Õß¡¢¿ÉÄÜΪADµ«ÁÙ´²Ö¢×´»ò²¡³Ì½øÕ¹²»µä·¶µÄ»¼Õß¡¢½øÕ¹ÐÔ³Õ´ô»¼Õß²¢ÇÒ·¢²¡ÄêÁäÔ磨< 65Ë꣩£¬ÎÒ¹úµÄÓ°Ïñѧ¹¤ÒµÓ¦¾¡¿ì¸ú½øѧÊõÑо¿µÄ½Å²½×ßÔÚ¹ú¼ÊµÄÇ°ÑØ
¡£

ͼ ¼Ö½¨¾ü½ÌÊÚ

 

ÉîÛÚÍåʵÑéÊÒ¹ùÌڷɲ©Ê¿¼°¹ãÖÝÒ½¿Æ´óѧÁ¥ÊôÄÔ¿ÆÒ½ÔºÖÓЦ÷½ÌÊÚ»®·ÖÕë¶ÔADÌåÒºÉúÎï±ê¼ÇÎïµÄ³£Óüì²âÒªÁì£¬¼´µ¥·Ö×Ó¼¼ÊõºÍ»¯Ñ§·¢¹â/µç»¯Ñ§·¢¹â¼¼ÊõµÄÓ¦ÓýøÐÐÁË·ÖÏí£¬Ö¸³öѪ½¬ÉúÎï±ê¼ÇÎï¼ì²â¾ßÓÐ΢´´ÐԺͱ㵱ÐÔ£¬±ãÓÚÁÙ´²Ê¹ÓÃ£¬ÔÚADÔçÆÚÕï¶ÏÖоßÓо޴óÓ¦ÓÃDZÁ¦£¬Èçp-Tau217ÊÇADÕï¶ÏºÜÊÇÓÐÇ°¾°µÄÉúÎï±ê¼ÇÎï£¬Äܹ»¾¡Ôç¼ì²âµ½ADµÄ²¡Àí±ä¸ï^[10]
¡£

ͼ ¹ùÌڷɲ©Ê¿

ͼ ÖÓЦ÷½ÌÊÚ

 

ÌåÒºÉúÎï±ê¼ÇÎïºÍÓ°ÏñѧÉúÎï±ê¼ÇÎï¿ÉÓ¦ÓÃÓÚADµÄÔçÆÚÕï¶Ï¡¢¾«×¼Ñ¡Ôñ¿É´ÓDMTÒ©ÎïÖлñÒæµÄAD»¼ÕßÒÔ¼°¼à²âÖÎÁÆ·´Ó¦µÈÒªº¦Àú³Ì£¬Ä¿½ñ²»µ«ÉúÎï±ê¼ÇÎïµÄÖÖÀ༰ЧÄÜÕýÔÚÔö¼Ó£¬Æä¼ì²âÒªÁìÒ²ÓÐÁ˸üÐÂ
¡£ÔÚ½áÊøÕâÒ»»·½ÚµÄ½²¿Îºó£¬ÔÚ¶Åâù·å½ÌÊÚµÄÖ÷³ÖÏÂ£¬ÖØÇìÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºÂÀÑó½ÌÊÚ¡¢±±¾©Ð­ºÍҽԺ볿êͽÌÊÚ¡¢¼ªÁÖ´óѧµÚÒ»Ò½ÔºËïÀò½ÌÊÚ¡¢½â·Å¾ü×ÜÒ½ÔºÕŽõÃ÷½ÌÊÚ¾ÍÖÚ¶àÉúÎï±ê¼ÇÎïµÄÁÙ´²Êµ¼ùÓ¦ÓÃÕ¹¿ªÁËÉîÈëÌÖÂÛ
¡£

ͼ ´ó¿§É³·¢Ðã

 

AD¿É·À¿É¿Ø£¬È«³Ì»ý¼«Ó¦¶Ô¿É¼õÇá¼²²¡µ£¸º

¡°È«Çò³Õ´ô»¼ÕßµÄÕÕ»¤ÏÖ×´¿°ÓÇ£¬ÇÒÕÕ»¤ÕßÃæÁÙµÄѹÁ¦Ò²½ûÖ¹ºöÊÓ
¡£¡±ÉϺ£Êо«ÉñÎÀÉúÖÐÐÄÀîϼ½ÌÊÚÔÚÊÚ¿ÎÖÐÖ¸³ö
¡£Àîϼ½ÌÊÚ·ÖÏíÁËSMARRTÑо¿ºÍFINGERÑо¿µÄ×îнá¹û£¬Í¨¹ýϵͳÐÔ¡¢¶àÁìÓòµÄ¸öÐÔ»¯¸ÉÔ¤¿ÉÏÔÖø¸ÄÉÆÊÜÊÔÕßÈÏÖª²¢Ìá¸ßÉú»îÖÊÁ¿£¬½µµÍADΣº¦£¬ÇÒÆä¸ÉÔ¤½á¹ûËƺõ²»ÊÜÒÅ´«ÒòËصÄÓ°Ï죻ǿÁÒ½¨ÒéÔÚÕû¸öÉúÃüÀú³ÌÖÐ£¬¶ÔÉú»î·½·¨¡¢ºÏ²¢Ö¢µÈÖصãÒòËØʵʩ¸ÉÔ¤^[11]
¡£

ͼ Àîϼ½ÌÊÚ

 

Õë¶Ô»¼ÕßÖÎÀíÕâÒ»ÖØÒªÒéÌâ£¬Õã½­´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½Ôº³Â쿽ÌÊÚ¡¢ÄϾ©Ò½¿Æ´óѧÁ¥ÊôÄÔ¿ÆҽԺʯ¾²Æ¼½ÌÊÚ¡¢ÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½ÔºÌÀÜö¶¬½ÌÊÚ¡¢¶«ÄÏ´óѧÁ¥ÊôÖдóҽԺл´ºÃ÷½ÌÊÚ¡¢¹ã¶«Ê¡ÈËÃñÒ½ÔºÕÔ½àð©½ÌÊÚ¾ÍÔçÆÚAD»¼ÕßµÄÈ«³ÌÖÎÀí£¬ÒÔ¼°ÔÚÁÙ´²ÉϽÓÊÜDMTÒ©ÎïÖÎÁƵÄAD»¼ÕߵĹ淶ÖÎÀí½øÐÐÁËÌÖÂÛ
¡£ÔÚÓÃÒ©Ç°½øÐÐÈ«ÃæÆÀ¹À¡¢Ñϸñɸ²é»¼ÕßÊÇAD¾«×¼ÓÃÒ©µÄ»ùʯ£¬¿É¶Ô»¼Õß¿ªÕ¹¸ü¾ßÕë¶ÔÐÔµÄÖÎÁÆ£¬ÓÃÒ©ºó½èÖúÊý×Ö»¯¹¤¾ß¿É×ÊÖúÁÙ´²Ò½Éú¼à²â»¼Õß²»Á¼·´Ó¦¡¢ÆÀ¹ÀÖÎÁÆЧ¹û
¡£

ͼ ´ó¿§É³·¢Ðã

 

С½á

±¾´Î´ó»áµÄÄÚÈÝÅöײÔÚADµÄ¶àÁìÓòÖÐÐò´Î¿ª»¨£¬Õï¶ÏÁìÓòÓжàÏîÉúÎï±ê¼ÇÎïÑо¿µÄ½øÕ¹£¬ÖÎÁÆÁìÓòÓÐÂØ¿¨Ä¹µÈÐÂÒ©ÖØ°õÉÏÊÐ£¬²¡Àí»úÖƵÄÑо¿Èç»ðÈçݱ£¬»¼ÕßÖÎÀíÓëÕÕ»¤Ò²Ã»Óб»ÎÒÃǺöÂÔ£¬¶à·½Ò»Í¬Å¬Á¦Íƽø¡°ÄÔ½¡¿µÐж¯¡±£¬²Å»ªÈá°ÈËÈËÏíÓÐÄÔ½¡¿µ¡±µÄÄ¿±ê×îÖո濢£¡

 

²Î¿¼ÎÄÏ×

[1] Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023 May 25;9(2):e12385.

[2]Tahami Monfared AA, Ye W, Sardesai A, et a;. A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial. Neurol Ther. 2023 Jun;12(3):863-881.

[3] Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis.

[4]Ou YN, Yang YX, Deng YT, et al. Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood. Mol Psychiatry. 2021 Oct;26(10):6065-6073.

[5]Vadukul DM, Vrancx C, Burguet P, et al. An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid-¦Â. Sci Rep. 2021 Jun 2;11(1):11570.

[6]Hardy J, Mummery C. An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next? Brain. 2023 Apr 19;146(4):1240-1242.

[7]van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023 Jan 5;388(1):9-21.

[8]Paroni G, Bisceglia P, Seripa D. Understanding the Amyloid Hypothesis in Alzheimer’s Disease. J Alzheimers Dis. 2019;68(2):493-510.

[9]Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023 May 25;9(2):e12385.

[10]Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772-781.

[11]Sindi S, Solomon A, K?reholt I, et al. Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):491-498.